EVOLVE Short DAPT Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2009 participants.

Also called NCT02605447

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,009 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02605447
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Germany, Japan, Latvia, Sweden, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02605447. Allocation not applicable; no masking; primary purpose treatment. Start 2016-02-16 (actual); primary completion 2019-07-17 (actual). Results posted on 2020-09-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EVOLVE Short DAPT Study
Intervention (Drug)
3 months of dual antiplatelet therapy (DAPT)
Intervention (Device)
SYNERGY Stent System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct02605447
Content hash
ae24579deed40d3534d4eb27e2ff8ae5b841a8aab239f9b68c554c8eb5ab3336